One of the most critical topics to address in health care today is the mental health and well-being of physicians and other ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...

Alnylam Pharmaceuticals’ RNAi therapeutic vutrisiran has been recommended by the European Medicines Agency’s human medicines ...

What impact can we expect from the abolition of NHS England (NHSE) and changes at the Department of Health and Social Care ...

The relationship between patient advocacy groups (PAGs) and pharmaceutical companies face challenges that if addressed could ...

Bristol Myers Squibb (BMS) has announced that an injectable version of its cancer immunotherapy Opdivo (nivolumab) has been ...

Novartis has announced that it will be acquiring Regulus Therapeutics in a deal worth $1.7bn, marking a notable boost to the ...

But the legal and regulatory framework is evolving to keep pace. The EU AI Act, GDPR and medical device regulations are ...

AZ’s triple-combination therapy is already approved under the brand names Breztri Aerosphere and Trixeo Aerosphere to treat ...